Sara Bradley

Sara Bradley

Morrison & Foerster LLP

Contact  |  View Bio  |  RSS

Latest Publications

Share:

Drones: When, Why, and How Will the FAA Investigate Unauthorized UAS Use?

On July 15, 2014, the Federal Aviation Administration (FAA) published its latest National Policy Notice concerning drones, titled “Education, Compliance, and Enforcement of Unauthorized Unmanned Aircraft Systems Operators.”...more

7/30/2014 - Airspace Aviation Industry Drones FAA Final Guidance Investigations unmann

Drones: Hollywood’s Requests for Regulatory Exemptions from the FAA Could Get UAS for Commercial Use Off the Ground

The lack of certainty regarding the use and regulation of unmanned aircraft systems (UAS) is prompting companies to seek creative ways to get their drones off the ground. This week, seven aerial photo and video production...more

6/5/2014 - Drones Entertainment Industry Exemptions FAA Oil & Gas Regulatory Standards Utilities Sector

Drones: A Bird’s-Eye View of the (Non-Privacy) Legal Landscape for UAS

A recent near midair collision between U.S. Airways Flight 4650, a CRJ-200 jet with a 50- passenger capacity, and a drone has (deservedly) sparked a flurry of commentary regarding safe drone operation. This near miss, which...more

5/21/2014 - Aircraft Airlines Aviation Industry Drones FAA Unmanned Aircraft Systems

$4 billion price tag? FDA's proposed generic drug labelling rule

An economic consulting group recently published findings that a Food and Drug Administration (FDA) proposed rule will increase annual healthcare costs by $4 billion. The FDA's proposal, announced in November 2013, will allow...more

3/14/2014 - FDA Generic Drugs Labeling Pharmaceutical Prescription Drugs

$4 Billion Price Tag for Pleasing Plaintiffs' Bar? New Study Estimates Costs of FDA's Proposed Rule on Generic Drug Labeling

An economic consulting group recently published findings that a Food and Drug Administration (FDA) proposed rule will increase annual healthcare costs by $4 billion. The FDA's proposal, announced in November 2013, would allow...more

2/27/2014 - FDA Generic Drugs Labeling PLIVA v Mensing Prescription Drugs SCOTUS

Proposed Changes to CPSA Section 6(b) Reduce Protections Currently Available to Manufacturers and Private Labelers

Section 6(b) of the CPSA establishes procedures for and restrictions on the CPSC’s public disclosure of information. It prohibits the CPSC from disclosing information about a consumer product that identifies a company unless...more

2/27/2014 - CPSC Disclosure Requirements Manufacturers

6 Results
|
View per page
Page: of 1